Adaptive Biotechnologies Corporation
ADPT
Rank in Stocks
#4180
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Share Price
$23.98
Last synced: 2026-10-19
Market Cap
$3.83B
Change (1 day)
-0.17%
Change (1 year)
34.49%
Country
US
Trade Adaptive Biotechnologies Corporation (ADPT)
Category
Healthcare
P/E ratio for Adaptive Biotechnologies Corporation (ADPT)
P/E ratio as of October 2026 TTM: -62.89
According to Adaptive Biotechnologies Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -62.89. At the end of 2024 the company had a P/E ratio of -5.53.
P/E ratio history for Adaptive Biotechnologies Corporation from 2017 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -62.89 | 51.86% |
| 2025 | -41.41 | 648.33% |
| 2024 | -5.53 | 76.19% |
| 2023 | -3.14 | -58.90% |
| 2022 | -7.64 | -60.10% |
| 2021 | -19.15 | -65.53% |
| 2020 | -55.56 | -12.15% |
| 2019 | -63.25 | -30.86% |
| 2018 | -91.48 | -7.79% |
| 2017 | -99.20 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -145.77% |
US
|
|
| -28.36 | -54.91% |
US
|
|
| -24.57 | -60.93% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -148.23% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.